An Evolutionary Approachs in Development of Needle Free Injection Technologies

The demand for novel drug delivery technologies is ever increasing though majority of the drugs are administered via oral, inhalation, transdermal and parenteral route. However, there are large numbers of therapies, particularly protein-based, gene-based and vaccine-based that cannot be delivered by this route for example insulin, growth hormones and other similar biologics. This emerging technique is a major sector in drug delivering system. It offers numbers of benefits for instances, reduced needle phobia, better patient compliance and reduce risk of needlestick injury. Moreover, this work by forcing liquid medication at high speed through a tiny orifice that is held against the skin. This creates an ultrafine stream of high pressure fluid that penetrates the skin without the use of a needle thus faster administration of drug compared to conventional needles. Its low cost provides benefits to patients and health professionals. Several technologies are available on the market including Ferring’s Zomajet 2 Vision, Merck Serono’s Saizen Cool.Click and Teva’s Tev-Tropin Tjet etc. There appear to be tremendous opportunity for needle-free technology to have major impact in the industry. It is likely that dramatic change may occur only when a large pharmaceutical or biotechnology company adopts needle free technology and demonstrates it needle free injections are well being supported by organizations like WHO and CDC (Centre for Disease Control). It become more feasible technology for injecting the protein based drug’s versatility, acceptance and value in major therapeutic area.